Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. A total of 121 patients (with 146 liver tumors) who underw...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-02, Vol.38 (2), p.945-954
Main Authors: Uemoto, Kenji, Doi, Hiroshi, Shiomi, Hiroya, Yamada, Koichi, Tatsumi, Daisaku, Yasumoto, Taku, Takashina, Masaaki, Koizumi, Masahiko, Oh, Ryoong-Jin
Format: Article
Language:English
Subjects:
Background radiation
Hepatocellular carcinoma
Liver
Liver cancer
Patients
Radiation
Radiation therapy
Tumors
α-Fetoprotein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c372t-6aeca9cfedc14f96e5389103c0094b8e0d64eacf4a75167dd631953e6c05f4b63
cites
container_end_page 954
container_issue 2
container_start_page 945
container_title Anticancer research
container_volume 38
creator Uemoto, Kenji
Doi, Hiroshi
Shiomi, Hiroya
Yamada, Koichi
Tatsumi, Daisaku
Yasumoto, Taku
Takashina, Masaaki
Koizumi, Masahiko
Oh, Ryoong-Jin
description This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. A total of 121 patients (with 146 liver tumors) who underwent SBRT between July 2007 and August 2016 were analyzed, regarding overall survival and local control (LC). The 2- and 5-year LC rates were 91.5% and 89.8%, respectively. Planning target volume (PTV) margin
doi_str_mv 10.21873/anticanres.12308
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1993013609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2137114633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-6aeca9cfedc14f96e5389103c0094b8e0d64eacf4a75167dd631953e6c05f4b63</originalsourceid><addsrcrecordid>eNpdkUFv1DAQhS0EokvhB3BBlrhwSWtnEjs-llWhSK0qleUczdoTcJXYi-0c9t9j2gISpznMe2-e5mPsrRRnrRw0nGMo3mJIlM9kC2J4xjZSG9noHsRzthFtLxotRH_CXuV8L4RSZoCX7KQ1oDvdqg0r29mHmjHzi5wp54VC4XHiN96m2NRg79a63K1LTJm7NfnwnX8tlCgWtPU6_xjdkd-h81h8DHz3gxIejnyKiV_RAUu0NM_rjIlvMVkf4oKv2YsJ50xvnuYp-_bpcre9aq5vP3_ZXlw3FnRbGoVk0diJnJXdZBT1MBgpwAphuv1AwqmO0E4d6l4q7ZwCaXogZUU_dXsFp-zDY-4hxZ8r5TIuPv-ug4HimkdpDAgJSpgqff-f9D6uKdR2YytBS9kpgKqSj6r6nJwTTeMh-QXTcZRifEAy_kMyPiCpnndPyet-IffX8YcB_AKMeYuu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137114633</pqid></control><display><type>article</type><title>Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</title><source>EZB Free E-Journals</source><creator>Uemoto, Kenji ; Doi, Hiroshi ; Shiomi, Hiroya ; Yamada, Koichi ; Tatsumi, Daisaku ; Yasumoto, Taku ; Takashina, Masaaki ; Koizumi, Masahiko ; Oh, Ryoong-Jin</creator><creatorcontrib>Uemoto, Kenji ; Doi, Hiroshi ; Shiomi, Hiroya ; Yamada, Koichi ; Tatsumi, Daisaku ; Yasumoto, Taku ; Takashina, Masaaki ; Koizumi, Masahiko ; Oh, Ryoong-Jin</creatorcontrib><description>This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. A total of 121 patients (with 146 liver tumors) who underwent SBRT between July 2007 and August 2016 were analyzed, regarding overall survival and local control (LC). The 2- and 5-year LC rates were 91.5% and 89.8%, respectively. Planning target volume (PTV) margin &lt;8 mm was associated with poor LC. Of the 77 patients with PTV margin of &lt;8 mm, age &lt;75 years was associated with poor LC, while alpha-fetoprotein (AFP) ≤20 ng/ml was associated with good LC. In patients with high AFP levels, there is a possibility of microscopic invasion around the tumor, suggesting that LC may be improved by adding an additional clinical target volume margin to the gross tumor volume.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12308</identifier><identifier>PMID: 29374726</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Background radiation ; Hepatocellular carcinoma ; Liver ; Liver cancer ; Patients ; Radiation ; Radiation therapy ; Tumors ; α-Fetoprotein</subject><ispartof>Anticancer research, 2018-02, Vol.38 (2), p.945-954</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Feb 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-6aeca9cfedc14f96e5389103c0094b8e0d64eacf4a75167dd631953e6c05f4b63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29374726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uemoto, Kenji</creatorcontrib><creatorcontrib>Doi, Hiroshi</creatorcontrib><creatorcontrib>Shiomi, Hiroya</creatorcontrib><creatorcontrib>Yamada, Koichi</creatorcontrib><creatorcontrib>Tatsumi, Daisaku</creatorcontrib><creatorcontrib>Yasumoto, Taku</creatorcontrib><creatorcontrib>Takashina, Masaaki</creatorcontrib><creatorcontrib>Koizumi, Masahiko</creatorcontrib><creatorcontrib>Oh, Ryoong-Jin</creatorcontrib><title>Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. A total of 121 patients (with 146 liver tumors) who underwent SBRT between July 2007 and August 2016 were analyzed, regarding overall survival and local control (LC). The 2- and 5-year LC rates were 91.5% and 89.8%, respectively. Planning target volume (PTV) margin &lt;8 mm was associated with poor LC. Of the 77 patients with PTV margin of &lt;8 mm, age &lt;75 years was associated with poor LC, while alpha-fetoprotein (AFP) ≤20 ng/ml was associated with good LC. In patients with high AFP levels, there is a possibility of microscopic invasion around the tumor, suggesting that LC may be improved by adding an additional clinical target volume margin to the gross tumor volume.</description><subject>Background radiation</subject><subject>Hepatocellular carcinoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Patients</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Tumors</subject><subject>α-Fetoprotein</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkUFv1DAQhS0EokvhB3BBlrhwSWtnEjs-llWhSK0qleUczdoTcJXYi-0c9t9j2gISpznMe2-e5mPsrRRnrRw0nGMo3mJIlM9kC2J4xjZSG9noHsRzthFtLxotRH_CXuV8L4RSZoCX7KQ1oDvdqg0r29mHmjHzi5wp54VC4XHiN96m2NRg79a63K1LTJm7NfnwnX8tlCgWtPU6_xjdkd-h81h8DHz3gxIejnyKiV_RAUu0NM_rjIlvMVkf4oKv2YsJ50xvnuYp-_bpcre9aq5vP3_ZXlw3FnRbGoVk0diJnJXdZBT1MBgpwAphuv1AwqmO0E4d6l4q7ZwCaXogZUU_dXsFp-zDY-4hxZ8r5TIuPv-ug4HimkdpDAgJSpgqff-f9D6uKdR2YytBS9kpgKqSj6r6nJwTTeMh-QXTcZRifEAy_kMyPiCpnndPyet-IffX8YcB_AKMeYuu</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Uemoto, Kenji</creator><creator>Doi, Hiroshi</creator><creator>Shiomi, Hiroya</creator><creator>Yamada, Koichi</creator><creator>Tatsumi, Daisaku</creator><creator>Yasumoto, Taku</creator><creator>Takashina, Masaaki</creator><creator>Koizumi, Masahiko</creator><creator>Oh, Ryoong-Jin</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</title><author>Uemoto, Kenji ; Doi, Hiroshi ; Shiomi, Hiroya ; Yamada, Koichi ; Tatsumi, Daisaku ; Yasumoto, Taku ; Takashina, Masaaki ; Koizumi, Masahiko ; Oh, Ryoong-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-6aeca9cfedc14f96e5389103c0094b8e0d64eacf4a75167dd631953e6c05f4b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Background radiation</topic><topic>Hepatocellular carcinoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Patients</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Tumors</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uemoto, Kenji</creatorcontrib><creatorcontrib>Doi, Hiroshi</creatorcontrib><creatorcontrib>Shiomi, Hiroya</creatorcontrib><creatorcontrib>Yamada, Koichi</creatorcontrib><creatorcontrib>Tatsumi, Daisaku</creatorcontrib><creatorcontrib>Yasumoto, Taku</creatorcontrib><creatorcontrib>Takashina, Masaaki</creatorcontrib><creatorcontrib>Koizumi, Masahiko</creatorcontrib><creatorcontrib>Oh, Ryoong-Jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uemoto, Kenji</au><au>Doi, Hiroshi</au><au>Shiomi, Hiroya</au><au>Yamada, Koichi</au><au>Tatsumi, Daisaku</au><au>Yasumoto, Taku</au><au>Takashina, Masaaki</au><au>Koizumi, Masahiko</au><au>Oh, Ryoong-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>38</volume><issue>2</issue><spage>945</spage><epage>954</epage><pages>945-954</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. A total of 121 patients (with 146 liver tumors) who underwent SBRT between July 2007 and August 2016 were analyzed, regarding overall survival and local control (LC). The 2- and 5-year LC rates were 91.5% and 89.8%, respectively. Planning target volume (PTV) margin &lt;8 mm was associated with poor LC. Of the 77 patients with PTV margin of &lt;8 mm, age &lt;75 years was associated with poor LC, while alpha-fetoprotein (AFP) ≤20 ng/ml was associated with good LC. In patients with high AFP levels, there is a possibility of microscopic invasion around the tumor, suggesting that LC may be improved by adding an additional clinical target volume margin to the gross tumor volume.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>29374726</pmid><doi>10.21873/anticanres.12308</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0250-7005
ispartof Anticancer research, 2018-02, Vol.38 (2), p.945-954
issn 0250-7005
1791-7530
language eng
recordid cdi_proquest_miscellaneous_1993013609
source EZB Free E-Journals
subjects Background radiation
Hepatocellular carcinoma
Liver
Liver cancer
Patients
Radiation
Radiation therapy
Tumors
α-Fetoprotein
title Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A29%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Assessment%20of%20Micro-residual%20Tumors%20during%20Stereotactic%20Body%20Radiation%20Therapy%20for%20Hepatocellular%20Carcinoma&rft.jtitle=Anticancer%20research&rft.au=Uemoto,%20Kenji&rft.date=2018-02-01&rft.volume=38&rft.issue=2&rft.spage=945&rft.epage=954&rft.pages=945-954&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12308&rft_dat=%3Cproquest_cross%3E2137114633%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-6aeca9cfedc14f96e5389103c0094b8e0d64eacf4a75167dd631953e6c05f4b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2137114633&rft_id=info:pmid/29374726&rfr_iscdi=true